Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer

Active, not recruitingOBSERVATIONAL
Enrollment

4,000

Participants

Timeline

Start Date

August 21, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

February 28, 2025

Conditions
Non-small Cell Lung Cancer Metastatic
Interventions
OTHER

Predictive models (data collection)

Machine learning predictive models

Trial Locations (30)

14203

Roswell Park Comprehensive Cancer Center, Buffalo

28040

Fundacion jimenez diaz, Madrid

28222

Puerta De Hierro Hospital, Madrid

33100

Azienda Sanitaria Universitaria Friuli Centrale (ASU FC), Udine

43100

University Hospital Of Parma, Parma

44093

CHU de Nantes, Nantes

46009

Instituto Valenciano De Oncologia, Valencia

52242

Holden Comprehensive Cancer Center at University of Iowa Health Care, Iowa City

53705

Carbone Comprehensive Cancer Center at University of Wisconsin, Madison

55905

Mayo Clinic, Rochester

69002

Hospices Civils de Lyon, Lyon

75013

La Pitié Salpêtrière, Paris

75020

Tenon Hospital, Paris

83100

Centre Hospitalier de Toulon, Toulon

84112

Huntsman Cancer Institute, Salt Lake City

92100

Ambroise Paré Hospital, Boulogne-Billancourt

92150

Foch Hospital, Suresnes

93000

Avicenne Hospital, Bobigny

01655

UMASS Memorial Health, Worcester

71681-603

DASA - Hospital Brasilia, Brasília

24020-096

DASA - Hospital de Niteroi, Niterói

22061-080

DASA - Hospital São Lucas, Rio de Janeiro

01409-902

DASA - Hospital Nove De Julho, São Paulo

Unknown

AC Camargo, São Paulo

Sunnybrook Health Sciences Centre Toronto, Toronto

CHU Bordeaux, Bordeaux

Shaare Zadek Medical Center, Jerusalem

Sourasky Medical Center, Tel Aviv

Policlinico Gemelli, Roma

04103

University Hospital Leipzig, Leipzig

All Listed Sponsors
lead

Sophia Genetics SAS

INDUSTRY